Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • TRIJARDY® XR - Healthy
    Clinical Study Number 1361.1
    Study Indication Healthy
    Product TRIJARDY® XR
    Generic Name Empagliflozin + Linagliptin + Metformin
    Lab Code
    Clinical Phase I
    Study Title

    Bioequivalence of a fixed dose combination tablet of empagliflozin/linagliptin/metformin extended release compared to the free combination of empagliflozin, linagliptin, and metformin extended release tablets following oral administration in healthy male and female subjects (an open-label, randomised, single-dose, two-period, two-sequence crossover study)

    Study Document
    Trial synopsis 1361.1 english
  • TRIJARDY® XR - Healthy
    Clinical Study Number 1361-0003
    Study Indication Healthy
    Product TRIJARDY® XR
    Generic Name Empagliflozin + Linagliptin + Metformin
    Lab Code
    Clinical Phase I
    Study Title

    Bioequivalence of a fixed dose combination tablet of empagliflozin/linagliptin/metformin extended release compared to the free combination of empagliflozin, linagliptin, and metformin extended release tablets following oral administration in healthy male and female subjects (an open-label, randomised, single-dose, two-period, two-sequence crossover study)

    Study Document
    Trial synopsis 1361-0003 english
  • TRIJARDY® XR - Healthy
    Clinical Study Number 1361-0011
    Study Indication Healthy
    Product TRIJARDY® XR
    Generic Name Empagliflozin + Linagliptin + Metformin
    Lab Code
    Clinical Phase I
    Study Title

    Bioequivalence of a low strength fixed dose combination tablet of empagliflozin/linagliptin/metformin extended release compared to the free combination of empagliflozin, linagliptin, and metformin extended release tablets following oral administration in healthy male and female subjects (an open-label, randomised, single-dose, two-period, two-sequence crossover study)

    Study Document
    Trial synopsis 1361-0011 english
    Lay summary 1361-0011 english
  • TRIJARDY® XR - Hypertension
    Clinical Study Number 1348.6
    Study Indication Hypertension
    Product TRIJARDY® XR
    Generic Name Telmisartan + Amlodipine + Hydrochlorothiazide
    Lab Code
    Clinical Phase IV
    Study Title

    The special drug use-results survey on long-term use of telmisartan 80 mg/amlodipine 5 mg/hydrochlorothiazide 12.5 mg fixed dose combination tablets in Patients with Hypertension

    Study Document
    Trial synopsis 1348.6 english